Capital One analyst Zegbeh Jallah noted that Ideaya Biosciences provided its Q4 update and said it has a cash runway into 2026. The company has made "steady progress on its pipeline programs" and the firm said its Buy thesis "remains intact" after management announced plans to present 20 patients worth of data in first-line MUM patients, inclusive of ORR and PFS data, by mid 2023. Capital One maintains an Overweight rating and $29 price target on Ideaya shares.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on IDYA:
- Ideaya Biosciences reports Q4 EPS (50c), consensus (56c)
- IDEAYA Biosciences, Inc. Reports 2022 Financial Results and Provides Business Update
- Ideaya Biosciences initiated with an Outperform at RBC Capital
- Capital One more bullish on Ideaya Biosciences after study update
- Ideaya Biosciences price target raised to $26 from $22 at Oppenheimer
